SYMPTOMS, RISK CLASSIFICATION, AND SPLEEN SIZE IN JAK2 INHIBITOR-NAIVE MYELOFIBROSIS: IMPLICATIONS FOR JAK2 INHIBITOR TREATMENT
R. Scherber,A. Dueck,H. Geyer, H. Kosiorek,J. J. Kiladjian, S. Slot,S. Zweegman, P. Boekhorst,H. Schouten,F. Sackmann,A. Fuentes, D. Hernandez-Maraver,H. Pahl,F. Stegelmann, K. Doehner,K. Bonatz, A. Reiter, F. Boyer, G. Etienne,J. C. Ianotto, D. Ranta, L. Roy,J. Y. Cahn,C. Harrison,D. Radia, P. Muxi, N. Maldonado,C. Besses,F. Cervantes,P. Johansson,G. Barosi, A. Vannucchi,F. Passamonti,B. Andreasson,J. Samuelsson, G. Birgegard, X. Sun, J. Xu, P. Zhang, Z. Xu,T. Barbui, Z. Senyak, M. Grieshammer,A. Rambaldi,M. Ferrari,T. Lehmann,R. Mesa HAEMATOLOGICA（2016）
AI 理解论文
溯源树
样例
